Sickle cell disease (SCD) is increasingly encountered in adult primary care as survival improves, yet most preventable morbidity and cost still result from reactive crisis management rather than proactive disease modification. From the AAVBC's perspective, value-based care begins by initiating generic hydroxyurea at the first eligible encounter rather than deferring treatment to hematology. Despite being the cornerstone of therapy, hydroxyurea remains substantially underused, even though adherence markedly reduces vaso-occlusive crises, emergency visits, hospitalizations, and overall costs. Because chronic kidney disease is common in aging adults with SCD, renal function should be assessed before initiation and dosing adjusted appropriately, making timely prescribing both a clinical and cost-conscious intervention.
Drawing from current ASH and NHLBI guidance, AAVBC's Sickle Cell Anemia Quick Reference Guide focuses on the clinical decisions where primary care creates the greatest value. It highlights genotype-specific ICD-10 coding, HCC/RAF mapping, MEAT documentation, complication surveillance, renal-adjusted hydroxyurea dosing, and coordinated management of chronic kidney disease, pulmonary hypertension, depression, and other age-related comorbidities. Beyond acute vaso-occlusive crises, the guide positions primary care as the accountable medical home, emphasizing adherence support, preventive care, and shared management with hematology to preserve function, reduce avoidable hospitalizations, and improve long-term outcomes for an aging population with sickle cell disease.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of sickle cell anemia — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Sickle cell disease (SCD) is increasingly encountered in adult primary care as survival improves, yet most preventable morbidity and cost still result from reactive crisis management rather than proactive disease modification. From the AAVBC's perspective, value-based care begins by initiating generic hydroxyurea at the first eligible encounter rather than deferring treatment to hematology. Despite being the cornerstone of therapy, hydroxyurea remains substantially underused, even though adherence markedly reduces vaso-occlusive crises, emergency visits, hospitalizations, and overall costs. Because chronic kidney disease is common in aging adults with SCD, renal function should be assessed before initiation and dosing adjusted appropriately, making timely prescribing both a clinical and cost-conscious intervention.
Drawing from current ASH and NHLBI guidance, AAVBC's Sickle Cell Anemia Quick Reference Guide focuses on the clinical decisions where primary care creates the greatest value. It highlights genotype-specific ICD-10 coding, HCC/RAF mapping, MEAT documentation, complication surveillance, renal-adjusted hydroxyurea dosing, and coordinated management of chronic kidney disease, pulmonary hypertension, depression, and other age-related comorbidities. Beyond acute vaso-occlusive crises, the guide positions primary care as the accountable medical home, emphasizing adherence support, preventive care, and shared management with hematology to preserve function, reduce avoidable hospitalizations, and improve long-term outcomes for an aging population with sickle cell disease.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of sickle cell anemia — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
